Feasibility of Using Daily Home HNHF-O2 During Sleep and/or Daytime in Hypercapnic COPD Patients Following Recent (< 12 Wks.) Hospitalization for AECOPD for 90 Days
| Registry | NCT03221387 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; na, single group, masking: none, treatment |
| Enrollment | 30 (Actual) |
| Sponsor | Temple University (Other); collaborators: Fisher and Paykel Healthcare |
| Conditions | Pulmonary Disease, Chronic Obstructive, Hypercapnia, Hypoxia |
| Interventions | Humidified nasal high flow with oxygen (Device) |
| Dates | start 2017-09-10, primary completion 2019-12-15, completion 2019-12-15, first posted 2017-07-18, last updated 2021-06-07 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Pulmonary Disease, Chronic Obstructive All trials for Hypercapnia All trials of Humidified nasal high flow with oxygen
Humidified Nasal High-flow with Oxygen (HNHF-O2) therapy has been reported to have acute beneficial effects in patients with hypoxemic respiratory failure who have been hospitalized. The usefulness of this therapy in the outpatient setting is unproven. This pilot study will test the feasibility of using this therapy in the outpatient setting and its effects on sleep.
Humidified Nasal High-flow with Oxygen (HNHF-O2) therapy has been reported to have acute beneficial effects in patients with hypoxemic respiratory failure. HNHF-O2 may be beneficial in patients with COPD and chronic impairments in gas exchange, both hypoxemia as well as hypercapnia. HNHF-O2 may decrease work of breathing, reduce dyspnea, improve airway humidification, and potentially stabilize or reduce carbon dioxide levels. However, there is limited data showing the chronic effects of HNHF-O2 in patients with hypercapnic respiratory failure, specifically those discharged to home following hospitalization for an acute exacerbation. Data that demonstrates that HNHF-O2 is well tolerated, and stabilizes or improves gas exchange long term in patients with COPD is lacking. Similarly, data that demonstrates that this therapeutic regimen is feasible to provide to patients in the home environment are lacking. This is an open-labeled pilot study of thirty patients to determine the safety and feasibility of using the device in the outpatient management of patients with COPD. A subset of ten patients will have serial sleep studies to determine the effects, if any, on sleep.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Nasal high flow with oxygen | Other | Device: Humidified nasal high flow with oxygen | While in the clinic High Flow Nasal Cannula oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience. The subject will be discharged to home and instructed to use the high flow nasal cannula system at night and during the daytime while at home and resting. |
Sex: All, ages: 40 Years to any
Inclusion Criteria: * admitted to the hospital for an acute exacerbation of COPD within the past 12 weeks * have COPD as the primary diagnosis * have smoked > 10 pack years. * receiving supplemental oxygen as part of their usual clinical care. * willing to give informed consent Exclusion Criteria: * upper airway or nasal problems that prohibit the use of high flow oxygen * current use (≤ 4 weeks of study entry) of any PAP-therapy (e.g., CPAP or NPPV) * sleep apnea as follows: STOPBang scores ≥ 5 or STOPBang score ≥ 2 plus BMI > 35 kg/m2; or Berlin questionnaire scores suggesting high likelihood of sleep apnea with increased risk of sleep-related accident (e.g., occupation as a commercial driver or pilot); * excessive daytime sleepiness (i.e., either of High (>15) score on the Epworth Sleepiness Scale or "fall asleep" accident or "near miss" accident in prior 12 months).
| Milestone | Nasal High Flow With Oxygen |
|---|---|
| Started | 30 |
| Completed | 28 |
| Not completed | 2 |
Time frame: 90 days
| Arm | Deaths | Serious adverse events | Other adverse events |
|---|---|---|---|
| Nasal High Flow With Oxygen | 0/28 (0.0%) | 0/28 (0.0%) | 0/28 (0.0%) |
Limitations and caveats: Single center study; no active control group; feasibility study
| Facility | City | Country | Status |
|---|---|---|---|
| Temple University Hospital | Philadelphia, Pennsylvania | United States |